AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Hodgkin’s Lymphoma Drugs Market – Advances in Diagnostic Methods to Boost Growth through 2019-2023 | Technavio

November 4, 2019 GMT
Hodgkin’s Lymphoma Drugs Market – Advances in Diagnostic Methods to Boost Growth through 2019-2023 | Technavio
Hodgkin’s Lymphoma Drugs Market – Advances in Diagnostic Methods to Boost Growth through 2019-2023 | Technavio

LONDON--(BUSINESS WIRE)--Nov 4, 2019--

According to a recent Technavio report, the Hodgkin’s lymphoma drugs market is expected to grow by USD 1.24 billion during 2019-2023. Growth in the Hodgkin’s lymphoma drugs market can be attributed to many segments, one of which is the type segment comprising of targeted therapy and chemotherapy. Industry participants are focusing on analyzing maximum growth opportunities in the market by considering their prospects in the fast-growing type segment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104005652/en/

Technavio has announced its latest market research report titled global hodgkin’s lymphoma drugs market 2019-2023. (Graphic: Business Wire)

What are the Latest Trends?

Patients suffering from Hodgkin’s Lymphoma in the initial stage are diagnosed using diagnostic methods such as imaging tests, blood tests, and physical examination. Advanced Hodgkin’s lymphoma biopsy such as excision biopsy and core needle biopsy are used to confirm the diagnosis. Excision biopsy is gaining traction in the market as it ensures accurate diagnosis and staging of lymphoma in patients. As per Technavio, the Hodgkin’s lymphoma drugs market is forecast to grow at a CAGR of close to 16% by 2023.

Get A Free Sample Analysis from theHodgkin’s Lymphoma Drugs Market Analysis

Doctors are adopting advanced imaging tests such as Positron Emission Tomography-Computed Tomography (PET-CT) scan to decide treatment options for patients by determining the stage of Hodgkin’s lymphoma.

In addition, A PET scan is combined with a CT to detect whether the lymphoma has spread to the bone marrow. It is done with the help of a three-dimensional color image of the affected area.

Register for a free trial today and gain instant access to 10,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Developments in the field of Hodgkin’s Lymphoma Drugs

Several vendors in the market are collaborating with pharmaceutical companies to co-develop and co-commercialize drugs for multiple types of cancer. For instance, Merck & Co., Inc. and AstraZeneca, through strategic oncology collaboration, co-developed and co-commercialized Lynparza (olaparib) for multiple types of cancer.

Bristol-Myers Squibb Company is one of the several vendors operating in the Hodgkin’s lymphoma drugs space, and the company collaborated with the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute to accelerate immuno-oncology research.

For Further Market Information

More insights like this on the U.S. and global markets can be found in a series of reports published by Technavio entitled the Mantle Cell Lymphoma Therapeutics Market Analysis, Size, Trends | Global | 2019-2023 & Anaplastic Lymphoma Kinase (ALK) Inhibitors Market Analysis, Size, Trends | Global | 2019-2023.

Email us at media@technavio.com or register online for a brochure and synopsis

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

Technavio is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, pharmaceutical and more Healthcare industries.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005652/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email:media@technavio.com

Website: https://www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Technavio Research

Copyright Business Wire 2019.

PUB: 11/04/2019 02:30 PM/DISC: 11/04/2019 02:30 PM

http://www.businesswire.com/news/home/20191104005652/en